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Introduction {#sec001}
============

Severe malaria results in the dysfunction of one or more vital organs \[[@pone.0235014.ref001]\]. *Plasmodium ovale*, which causes tertian malaria, was first reported in 1922 as one of the five *Plasmodium* species that can infect humans \[[@pone.0235014.ref002]\]. *P*. *ovale* accounts for between 0.5 and 10.5% of all malaria cases, and it is geographically distributed in sub-Saharan Africa, the Western Pacific, Timor, and Indonesia \[[@pone.0235014.ref003]\]. The highest prevalence of *P*. *ovale* has been reported in Papua New Guinea (15%) \[[@pone.0235014.ref004]\] and Nigeria (15%) \[[@pone.0235014.ref005]\]. However, the most recent retrospective cohort study conducted in Papua, Indonesia during 2004--2013 demonstrated a low prevalence of *P*. *ovale* infections (0.06%) among 68,361 patients \[[@pone.0235014.ref006]\]. Other recent studies demonstrated that *P*. *ovale* infections accounted for 2.5% of malaria cases in Uganda \[[@pone.0235014.ref007]\] and 2.7% of malaria cases in China \[[@pone.0235014.ref008]\]. Infections due to *P*. *ovale* have been underestimated compared with those of other *Plasmodium* species, as *P*. *ovale* has been demonstrated to lead to low parasitemia and have morphologic similarities with *P*. *vivax* and mixed infections \[[@pone.0235014.ref009], [@pone.0235014.ref010]\]. Similar to *P*. *vivax*, *P*. *ovale* can cause relapsing infection due to the presence of latent parasites (hypnozoites) in the liver long after the first treatment is administered with anti-malarial drugs \[[@pone.0235014.ref003]\]. *P*. *ovale* is detected and identified with the standard microscopic method. Rapid diagnostic tests (RDTs) can also be used in cases where microscopic detection cannot be performed, such as in rural or remote areas. However, the sensitivity of RDTs to detect *P*. *ovale* is low (22.2%) \[[@pone.0235014.ref011]\]. The low sensitivity of RDTs can be attributed to the low parasitemia level \[[@pone.0235014.ref012], [@pone.0235014.ref013]\] or different targeted antigens \[[@pone.0235014.ref014]\]. Recently, a molecular method with nested polymerase chain reaction (nested PCR) has been used to identify *Plasmodium* species \[[@pone.0235014.ref015]\]. Although continuous efforts regarding PCR techniques have been made to develop new diagnostic techniques, such as *Plasmodium* species-specific PCR-restriction fragment length polymorphism (PCR-RFLP) \[[@pone.0235014.ref016]\], for identifying malaria parasites, nested PCR techniques with high sensitivity and specificity are needed.

According to the molecular technique, two subspecies of *P*. *ovale*, *curtisi* and *P*. *ovale wallikeri*, were identified in 2010 by a nested PCR detection assay of dimorphism in the gene encoding the *P*. *ovale* tryptophan-rich antigen (potra) in West Africa \[[@pone.0235014.ref017]\]. Currently, *P*. *falciparum* is still the leading cause of severe malaria \[[@pone.0235014.ref018]\]. *P*. *ovale* is usually associated with low morbidity and mortality. However, *P*. *ovale* can cause severe complications and death \[[@pone.0235014.ref019], [@pone.0235014.ref020]\]. Previous studies have reported that the severe complications of *P*. *ovale* infections include acute respiratory distress syndrome (ARDS) \[[@pone.0235014.ref021]--[@pone.0235014.ref026]\], renal impairment \[[@pone.0235014.ref024], [@pone.0235014.ref027]\], jaundice, and hypotension \[[@pone.0235014.ref026], [@pone.0235014.ref027]\]. The most recent study on severe *P*. *ovale* malaria in travelers and migrants demonstrated that 5.3% of patients with *P*. *ovale* developed severe complications according to the 2015 WHO criteria, including hyperbilirubinemia, pulmonary edema, shock, significant bleeding, and impaired consciousness \[[@pone.0235014.ref028]\]. There are a limited number of systematic reviews and meta-analyses on severe *P*. *ovale* malaria. A previous systematic review of 33 articles published between 1922 and 2015 demonstrated that a total of five out of 22 severe cases of *P*. *ovale* malaria were fatal, and two cases of congenital *P*. *ovale* malaria were fatal \[[@pone.0235014.ref029]\]. A more recent systematic review conducted by Yerlikaya et al. in 2018 demonstrated that a RDT had poor performance in detecting *P*. *ovale* because *P*. *ovale* infections usually occur at very low parasite densities, leading to missed detection by microscopy and RDTs \[[@pone.0235014.ref030]\]. Nevertheless, studies on the prevalence of severe *P*. *ovale* malaria provide more information on this neglected species and are urgently needed. This systematic review and meta-analysis aimed to investigate the severity and mortality rates of severe *P*. *ovale* infection to increase the awareness of physicians regarding the prognosis of this severe disease and outcome-related deaths in countries in which this disease is endemic and to identify the differences in the proportions of patients with severe *P*. *ovale* manifestations and with other severe *Plasmodium* spp. infections.

Methods {#sec002}
=======

Study selection {#sec003}
---------------

This systematic review was designed on the basis of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines ([S1 Checklist](#pone.0235014.s001){ref-type="supplementary-material"}). Two authors (MK and KUK) searched the Medline, Scopus, and ISI Web of Science databases independently for articles published in English prior to January 5, 2020. Additional articles from other databases were also selected. The search terms, which included the Boolean operators "OR" or "AND", were as follows: "(severe OR complicated OR complication) AND (Plasmodium ovale)" ([S1 Table](#pone.0235014.s002){ref-type="supplementary-material"}). EndNote software version X7 (Thomson Reuters, New York, NY) was used to process all references in our study.

Quality of the included studies {#sec004}
-------------------------------

The quality of the observational studies was assessed in accordance with the Newcastle-Ottawa Scale (NOS) \[[@pone.0235014.ref031]\]. A \'star system\', in which a study is judged on the basis of the following three broad perspectives was used: the selection of the study groups; the comparability of the groups; and the ascertainment of either the exposure or outcome of interest.

Data extraction {#sec005}
---------------

All raw and available data from eight studies were extracted to explore the prevalence of severe complications in patients with *P*. *ovale* infections. Two authors (MK and KUK) extracted the data from the selected studies. If there were any discrepancies between the two reviewers, another reviewer (GM) determined whether the study should be included. For the prevalence outcome of severe *P*. *ovale* malaria, all prospective cohort, cross-sectional studies, and case-control studies that reported the number of patients with severe complications from *P*. *ovale* were included. The following articles were excluded from our study: book and book chapter reviews, conference papers, editorials, letters, correspondences, notes, reviews, animal studies, case reports, drug studies and clinical trials, entomological studies, experimental studies, knowledge assessments, studies written in local languages, studies on mixed infections of *P*. *ovale* and other *Plasmodium* spp., studies of *P*. *ovale* during pregnancy, prevalence studies of non-*P*. *ovale* infections, and prevalence studies of *P*. *ovale* that did not report data on severe complications.

Statistical analysis {#sec006}
--------------------

The primary outcome of the present study was the pooled prevalence of severe *P*. *ovale* infections and mortality rates. The number of severe *P*. *ovale* infections and the total number of *P*. *ovale* infections were entered into an Excel data sheet (Microsoft Corporation, USA). The pooled prevalence of the severity of *P*. *ovale* mono-infections was estimated using the command "metaprop case population, random/fixed" available in STATA software version 15.0 (‎StataCorp LLC, USA). The results are presented as the pooled estimate and 95% confidence interval (CI). A meta-regression with the median age as a covariate was performed to evaluate whether the age of the participants was a confounder of the pooled prevalence of severe *P*. *ovale*.

The secondary outcome of the present study was the different proportions of severity between patients with *P*. *ovale* and those with other *Plasmodium* species. The meta-analyses of the proportions were performed using a random-effects model provided in Review Manager 5.3 software (Cochrane Community). The heterogeneity was assessed with the Mantel-Haenszel method, and the I^2^ values were also calculated. The I^2^ was considered low (\<25%), moderate (25--50%), or high (\>50%). A fixed-effects model was used when I^2^\<50%, whereas a random-effects model was used when I^2^\>50%. The publication bias was also assessed using funnel plots.

Results {#sec007}
=======

Characteristics of included studies {#sec008}
-----------------------------------

A total of 1,504 articles were retrieved from three databases during the search, and eight of these articles, including retrospective studies, prospective studies, and case series, were included in this study ([Fig 1](#pone.0235014.g001){ref-type="fig"}). The characteristics of the eight studies are shown in [Table 1](#pone.0235014.t001){ref-type="table"}. The studies were conducted in Belgium (2000--2005) \[[@pone.0235014.ref032]\], the Ivory Coast (2007--2008) \[[@pone.0235014.ref033]\], the US National Malaria Surveillance System (NMSS) (1985--2011) \[[@pone.0235014.ref019]\], Indonesia (2004--2013) \[[@pone.0235014.ref034]\], Ethiopia (2013--2014) \[[@pone.0235014.ref035]\], Italy (2014--2017) \[[@pone.0235014.ref036]\], Spain (2005--2011) \[[@pone.0235014.ref037]\], and Sweden (1995--2015) \[[@pone.0235014.ref038]\]. The ages of the participants were reported in seven of the included studies \[[@pone.0235014.ref032]--[@pone.0235014.ref038]\], as they were not reported in a study by Hwang et al. \[[@pone.0235014.ref019]\]. Five studies reported severe imported *P*. *ovale* infections in European countries, including Belgium \[[@pone.0235014.ref032]\], France \[[@pone.0235014.ref033]\], Italy \[[@pone.0235014.ref036]\], Spain \[[@pone.0235014.ref037]\], and Sweden \[[@pone.0235014.ref038]\], while other studies reported severe *P*. *ovale* infections in the United States of America \[[@pone.0235014.ref019]\], Indonesia \[[@pone.0235014.ref034]\], and Ethiopia \[[@pone.0235014.ref035]\]. Most of the included studies (7/8, 87.5%) used microscopy as the gold standard for malaria identification, except for a study conducted by Ramos et al. in 2016 \[[@pone.0235014.ref035]\]. The combination of microscopy and PCR was used in three of the included studies \[[@pone.0235014.ref019], [@pone.0235014.ref036], [@pone.0235014.ref037]\]. Most of the *Plasmodium* spp. infections that were reported among the included studies were caused by *P*. *falciparum* (116,898 cases, 51%), *P*. *vivax* (78,282 cases, 34.1%), mixed infection (26,049 cases, 11.4%), *P*. *malariae* (6,428 cases, 2.8%), and *P*. *ovale* (1,365 cases, 0.6%).

![Flow diagram.\
Flow chart of the study selection process.](pone.0235014.g001){#pone.0235014.g001}

10.1371/journal.pone.0235014.t001

###### Characteristics of the included studies.

![](pone.0235014.t001){#pone.0235014.t001g}

  No.                   Reference                  Study area (years of the survey)   Participants                                   Age range              Reference method for malaria identification   *Plasmodium* sp.   Severe malaria   Fetal         Impaired consciousness   Prostration   Severe anemia   Renal impairment   Hyperbilirubinemia   Pulmonary    Significant bleeding   Shock
  --------------------- -------------------------- ---------------------------------- ---------------------------------------------- ---------------------- --------------------------------------------- ------------------ ---------------- ------------- ------------------------ ------------- --------------- ------------------ -------------------- ------------ ---------------------- ---------
  1\.                   Bottieau et al., 2006      Belgium (2000--2005)               Travelers, expatriates, and foreign Visitors   35 (11--77)            Microscopy                                    Pv = 48            Pv = 8                                                                                                   Pv = 8                                                   
  Po = 34               Po = 4                     Po = 4                                                                                                                                                                                                                                                                                                                                      
  Pm = 16               Pm = 3                     Pm = 3                                                                                                                                                                                                                                                                                                                                      
  2                     de Laval et al., 2010      France (2007--2008)                French soldiers                                32 (30--36)            Microscopy                                    Case series        Po = 1                                                                                                   Po = 1                                                   
  Po = 6                                                                                                                                                                                                                                                                                                                                                                                       
  3\.                   Hwang et al., 2014         USA (1985--2011)                   Travelers                                      NA                     Microscopy, PCR                               Pf = 15,272        Pf = 1,416       Pf = 122      Pf = 514                               Pf = 140        Pf = 503                                Pf = 176                            
  Pv = 12,152           Pv = 163                   Pv = 10                            Pv = 37                                        Pv = 16                Pv = 48                                       Pv = 35                                                                                                                                                                              
  Po = 903              Po = 18                    Po = 2                             Po = 4                                         Po = 6                 Po = 6                                        Po = 4                                                                                                                                                                               
  Pm = 1254             Pm = 22                    Pm = 2                             Pm = 2                                         Pm = 3                 Pm = 7                                        Pm = 2                                                                                                                                                                               
  Mixed = 226           Mixed = NA                                                                                                                                                                                                                                                                                                                                                             
  4\.                   Langford et al., 2015      Indonesia (2004--2013)             Patients presenting to the hospital            \<1                    Microscopy                                    Pf = 100,078       Pf = 4,031                                                            Pf = 2,521      Pf = 415                                Pf = 1,095                          
  1-\<5                 Pv = 65,306                Pv = 2,118                         Pv = 1,099                                     Pv = 81                Pv = 938                                                                                                                                                                                                                           
  5-\<15                Po = 0                     Po = 0                             Po = 1                                                                                                                                                                                                                                                                                                   
  ≥ 15                  Po = 120                   Po = 1                             Pm = 100                                       Pm = 16                Pm = 44                                                                                                                                                                                                                            
  Pm = 5,097            Pm = 160                   Mixed = 782                        Mixed = 84                                     Mixed = 343                                                                                                                                                                                                                                               
  Mixed = 25,779        Mixed = 1,209                                                                                                                                                                                                                                                                                                                                                          
  5\.                   Ramos et al., 2016         Ethiopia (2013--2014)              Patients with severe anemia                    15 (0.5--65)           PCR                                           111                Pf = 18                                                               Pf = 18                                                                                     
  Pv = 4                Pv = 4                                                                                                                                                                                                                                                                                                                                                                 
  Po = 4                Po = 4                                                                                                                                                                                                                                                                                                                                                                 
  6\.                   Rojo-Marcos et al., 2018   Italy (2014--2017)                 Patients with imported *P*. *ovale*            35 (22.2--53)          Microscopy, PCR                               79                 Po = 5                                                                Po = 1                             Po = 4                                                   
  7\.                   Rojo-Marcos et al., 2014   Spain (2005--2011)                 Patients with imported *P*. *ovale*            36.5 (11.8--52.7)      Microscopy, PCR                               35                 Po = 3                                                                Po = 2                                                  Po = 1                              
  8\.                   Wangdahl et al., 2019      Sweden (1995--2015)                Travelers and Migrants                         All = 32.6 (0.2--83)   Microscopy                                    Pf = 1,548         Pf = 146         Pf = 3        Pf = 28                  Pf = 9        Pf = 16         Pf = 31            Pf = 66              Pf = 15      Pf = 17                Pf = 33
  Pv = 776              Pv = 60                    Pv = 0                             Pv = 1                                         Pv = 1                 Pv = 15                                       Pv = 1             Pv = 28          Pv = 4        Pv = 5                   Pv = 8                                                                                                    
  Pf = 34.4 (0.2--83)   Po = 188                   Po = 10                            Po = 0                                         Po = 1                 Po = 0                                        Po = 0             Po = 0           Po = 6        Po = 2                   Po = 1        Po = 2                                                                                      
  Pm = 61               Pm = 2                     Pm = 0                             Pm = 0                                         Pm = 0                 Pm = 1                                        Pm = 0             Pm = 0           Pm = 0        Pm = 0                   Pm = 1                                                                                                    
  Pv = 29.9 (1--79)     Mixed = 44                 Mixed = 8                          Mixed = 1                                      Mixed = 1              Mixed = 0                                     Mixed = 4          Mixed = 3        Mixed = 4     Mixed = 0                Mixed = 1     Mixed = 3                                                                                   
  Pm = 30.2 (3--65)                                                                                                                                                                                                                                                                                                                                                                            
  Po = 30.2 (3--65)                                                                                                                                                                                                                                                                                                                                                                            
                                                   Total cases                                                                                                                                            Pf = 116,898       Pf = 5,611       Pf = 125      Pf = 542                 Pf = 9        Pf = 395        Pf = 949           Pf = 66              Pf = 1,286   Pf = 17                Pf = 33
  Pv = 78,282           Pv = 2,353                 Pv = 10                            Pv = 38                                        Pv = 1                 Pv = 1,134                                    Pv = 130           Pv = 36          Pv = 977      Pv = 5                   Pv = 8                                                                                                    
  Po = 1,365            Po = 46                    Po = 2                             Po = 5                                         Po = 2                 Po = 13                                       Po = 6             Po = 15          Po = 8        Po = 1                   Po = 2                                                                                                    
  Pm = 6,428            Pm = 187                   Pm = 2                             Pm = 2                                         Pm = 2                 Pm = 104                                      Pm = 23            Pm = 3           Pm = 46       Pm = 0                   Pm = 1                                                                                                    
  Mixed = 26,049        Mixed = 1,217              Mixed = 1                          Mixed = 1                                      Mixed = 1              Mixed = 786                                   Mixed = 87         Mixed = 4        Mixed = 343   Mixed = 1                Mixed = 3                                                                                                 

Prevalence of severe *P*. *ovale* infections {#sec009}
--------------------------------------------

Among the eight included studies, which included a total of 1,365 ovale malaria cases, the pooled prevalence of severe *P*. *ovale* was 0.03 (95% CI = 0.03--0.05%, I^2^ = 54.4%). The highest proportions of severe *P*. *ovale* were found in the study by de Laval et al. \[[@pone.0235014.ref033]\] (OR = 0.17, 95% CI = 0.03--0.56) and the study by Bottieau et al. \[[@pone.0235014.ref032]\] (OR = 0.12, 95% CI = 0.05--0.27), whereas the lowest proportion was found in the study by Langford et al., 2015 \[[@pone.0235014.ref034]\] ([Fig 2](#pone.0235014.g002){ref-type="fig"}). According to the results of the meta-regression of six included studies, the age of the participants did not confound to the pooled prevalence of severe *P*. *ovale* infections (P-value = 0.3, 95% CI = -0.002--0.005). The complications most commonly found in patients with *P*. *ovale* infections were jaundice (1.1%), severe anemia (0.88%), and pulmonary impairments (0.59%) ([Table 2](#pone.0235014.t002){ref-type="table"}).

![Pooled prevalence of severe *P*. *ovale* infections.\
Forest plot comparing the proportions of severe *P*. *ovale* cases and *P*. *vivax* cases.](pone.0235014.g002){#pone.0235014.g002}

10.1371/journal.pone.0235014.t002

###### Complications associated with *P*. *ovale*.

![](pone.0235014.t002){#pone.0235014.t002g}

  Major complication (WHO, 2014)   Total number of patients with a severe case   Proportion of complications (%) among the total number of *P*. *ovale* cases (1,365 cases)
  -------------------------------- --------------------------------------------- --------------------------------------------------------------------------------------------
  Pulmonary impairment             8                                             0.59
  Cerebral malaria                 5                                             0.37
  Renal impairment                 6                                             0.44
  Prostration                      2                                             0.15
  Hypotension/shock                2                                             0.15
  Jaundice                         15                                            1.10
  Severe anemia                    13                                            0.95
  Bleeding/DIC                     1                                             0.07

Comparison of severity between the *P*. *ovale* and *Plasmodium* spp. infections {#sec010}
--------------------------------------------------------------------------------

The meta-analysis of three included studies \[[@pone.0235014.ref019], [@pone.0235014.ref034], [@pone.0235014.ref038]\] demonstrated that a smaller proportion of patients with *P*. *ovale* than of patients with *P*. *falciparum* had severe infections (P-value = 0.01, OR = 0.36, 95% CI = 0.16--0.81, I^2^ = 72%) ([Fig 3](#pone.0235014.g003){ref-type="fig"}).

![Forest plot comparing severe *P*. *ovale* cases and *P*. *falciparum* cases.\
The forest plot compared the proportions of patients with severe *P*. *ovale* infections with that of patients with *P*. *falciparum* infections.](pone.0235014.g003){#pone.0235014.g003}

The meta-analysis of four studies \[[@pone.0235014.ref019], [@pone.0235014.ref032], [@pone.0235014.ref034], [@pone.0235014.ref038]\] revealed there are no significant differences in the proportion of patients with severe *P*. *ovale* infections and that of patients with severe *P*. *vivax* infections (P-value = 0.75, OR = 0.91, 95% CI = 0.5--1.65, I^2^ = 47%) ([Fig 4](#pone.0235014.g004){ref-type="fig"}).

![Forest plot comparing severe *P*. *ovale* cases and *P*. *vivax* cases.\
The forest plot compared the proportions of severe *P*. *ovale* cases and *P*. *vivax* cases.](pone.0235014.g004){#pone.0235014.g004}

The meta-analysis of four studies \[[@pone.0235014.ref019], [@pone.0235014.ref032], [@pone.0235014.ref034], [@pone.0235014.ref038]\] demonstrated that there was no significant difference between the proportion of patients with severe *P*. *ovale* infections and the proportion of patients with severe *P*. *malariae* infections (P-value = 0.75, OR = 0.92, 95% CI = 0.56--1.52, I^2^ = 0%) ([Fig 5](#pone.0235014.g005){ref-type="fig"}).

![Forest plot comparing severe *P*. *ovale* cases and *P*. *malariae* cases.\
Forest plot comparing the proportion of patients with severe *P*. *ovale* cases and the proportion of patients with *P*. *malaria* cases.](pone.0235014.g005){#pone.0235014.g005}

Mortality rates of *P*. *ovale* and *Plasmodium* spp. infections {#sec011}
----------------------------------------------------------------

There was only one study that reported death cases resulting from *P*. *ovale* infections \[[@pone.0235014.ref019]\].

The mortality rate of severe *P*. *ovale* infections in their study was 0.22% (2/903). The mortality rate of severe *P*. *ovale* infections among the eight included studies was 0.15% (2/1,365 cases). The mortality rate of other *Plasmodium* infections reported in the eight included studies was 0.11% for *P*. *falciparum* infections, 0.013% for *P*. *vivax* infections, 0.03% for *P*. *malariae* infections, and 0.004% for mixed infections.

Quality of included studies {#sec012}
---------------------------

Four studies were rated as having 9 stars (good quality), three studies were rated as having 7 stars (adequate quality), and one study was rated as having 6 stars (adequate quality) according to the NOS concerning the selection process for the cases and controls included ([Table 3](#pone.0235014.t003){ref-type="table"}).

10.1371/journal.pone.0235014.t003

###### Quality of the included studies.

![](pone.0235014.t003){#pone.0235014.t003g}

  No.   Reference                  Selection   Compatibility   Exposure                                    
  ----- -------------------------- ----------- --------------- ---------- ------- -------- ------- ------- -----------
  1\.   Bottieau et al., 2006      **✵**       **✵**           **✵**      **✵**   **✵✵**   **✵**   **✵**   ****✵****
  2     de Laval et al., 2010      **✵**       **✵**                              **✵✵**   **✵**   **✵**   **✵**
  3\.   Hwang et al., 2014         **✵**       **✵**           **✵**      **✵**   **✵✵**   **✵**   **✵**   **✵**
  4\.   Langford et al., 2015      **✵**       **✵**           **✵**      **✵**   **✵✵**   **✵**   **✵**   **✵**
  5\.   Ramos et al., 2016         **✵**                                          **✵✵**   **✵**   **✵**   **✵**
  6\.   Rojo-Marcos et al., 2018   **✵**       **✵**                              **✵✵**   **✵**   **✵**   **✵**
  7\.   Rojo-Marcos et al., 2014   **✵**       **✵**                              **✵✵**   **✵**   **✵**   **✵**
  8\.   Wangdahl et al., 2019      **✵**       **✵**           **✵**      **✵**   **✵✵**   **✵**   **✵**   **✵**

Publication bias {#sec013}
----------------

A funnel plot analysis of the included studies could not be performed to assess the publication bias among the included studies, as a minimum of 10 studies were required for the analysis \[[@pone.0235014.ref039]\].

Discussion {#sec014}
==========

The present systematic review and meta-analysis aimed to explore the prevalence of severe *P*. *ovale* infections and to summarize the mortality caused by *P*. *ovale*. The results demonstrated that 3% of patients infected with *P*. *ovale* developed severe complications according to the WHO 2014 guidelines \[[@pone.0235014.ref001]\]. Therefore, the term "benign malaria" might not apply to patients tested positive with *P*. *ovale*, especially travelers after returning from countries in which *P*. *ovale* is endemic. In addition, international and national healthcare providers should be recommending the use of chemoprophylaxis for travelers, as the present study revealed that *P*. *ovale*, long-recognized as benign malaria, can cause severe and fatal clinical manifestations. In the present study, a meta-regression with age as a covariate was performed, and the pooled prevalence of severe *P*. *ovale* infections was investigated. The results showed that the age of the participants in six of the included studies did not confound the pooled prevalence of severe *P*. *ovale* infections. A previous study demonstrated that the highest incidence of *P*. *ovale* was observed among children 0--7 years old, who had an 8-fold higher risk of *P*. *ovale* infections than did adults; nevertheless, clinical attacks were observed in all age groups \[[@pone.0235014.ref040]\].

The present study also demonstrated a significant difference between the proportion of patients with severe *P*. *ovale* infections and severe *P*. *falciparum* infections. A lower proportion of patients with severe *P*. *ovale* infections than of patients with *P*. *falciparum* infections had severe cases. This finding indicated that although *P*. *ovale* can cause severe malaria, the chance of patients developing severe complications is lower with *P*. *ovale* than with *P*. *falciparum*, which is the *Plasmodium* species widely known to be the leading cause of severe malaria in humans. This study also demonstrated there are no significant differences in the proportions of patients with severe *P*. *ovale* and with *P*. *vivax*/*P*. *malariae*. This finding demonstrated that there are relatively few severe *P*. *ovale* cases, including *P*. *vivax* and *P*. *ovale* cases. In contrast to *P*. *vivax*, which is endemic in Asia, Central America, and South America, *P*. *ovale* is only endemic in some African countries \[[@pone.0235014.ref003]\]. However, the study conducted by Langford et al. in 2015 \[[@pone.0235014.ref034]\] indicated that there were 120 cases of *P*. *ovale* infection in Indonesia, whereas other included studies reported that travelers who returned to their home countries had imported *P*. *ovale* malaria cases \[[@pone.0235014.ref019], [@pone.0235014.ref032], [@pone.0235014.ref035]--[@pone.0235014.ref038]\].

Although microscopy is still considered to be the gold standard for the identification of *Plasmodium* species, the morphological characteristics of *P*. *ovale* are similar to those of *P*. *vivax* and are readily missed by less experienced microscopists \[[@pone.0235014.ref041], [@pone.0235014.ref042]\]. This problem may have caused certain *P*. *ovale* cases to have been missed in the included studies conducted by Bottieau et al. \[[@pone.0235014.ref032]\], de Laval et al. \[[@pone.0235014.ref033]\], Langford et al. \[[@pone.0235014.ref034]\], and Wangdahl et al. \[[@pone.0235014.ref038]\], as only microscopy was used to identify malaria parasites. Missed *P*. *ovale* cases have been reported when only microscopy was used \[[@pone.0235014.ref043]\]. In addition, missed diagnoses of *P*. *ovale* infections leading to relapses with a low parasitemia level is a problem related to this *Plasmodium* species \[[@pone.0235014.ref044]\]. Previous studies have indicated that the sensitivity of routine microscopy in detecting *P*. *ovale* in imported cases is very low and related to low parasitemia levels \[[@pone.0235014.ref032], [@pone.0235014.ref045]\]. Moreover, the rapid diagnosis tests (RDTs) that have been developed and are available lack the sensitivity required to detect low amounts of the circulating antigen of *P*. *ovale* \[[@pone.0235014.ref046], [@pone.0235014.ref047]\]. Moreover, a previous study indicated that routine microscopic examinations with thick and thin blood smears should be repeated three times in cases of suspected imported *P*. *ovale* malaria \[[@pone.0235014.ref048]\]. Ideally, molecular detection using polymerase chain reaction (PCR) to detect and confirm *P*. *ovale* infections in cases of low parasitemia or negative blood film is needed, although it is not routinely available \[[@pone.0235014.ref032], [@pone.0235014.ref043]\]. Therefore, the limitations of routine microscopic and RDT tests might affect the management/treatment of patients and lead to an increase in the morbidity associated with *P*. *ovale* infections \[[@pone.0235014.ref049]\]. The mortality caused by severe *P*. *ovale* infections among travelers who returned to the USA was previously reported by Hwang et al. in 2014 \[[@pone.0235014.ref019]\]. The authors recommended the use of suppressive prophylaxis and antirelapse treatment with primaquine drugs for patients who returned from ovale-endemic countries \[[@pone.0235014.ref019]\]. Nevertheless, a previous case report showed that severe complications led to fatality in patients who had received anti-malarial prophylaxis treatment during their trip to Nigeria \[[@pone.0235014.ref020]\]. This finding may have been caused by the impropriate usage of prophylactic drugs or the survival of hypnozoites during anti-malaria chemoprophylaxis against the *P*. *ovale* infection \[[@pone.0235014.ref050]\].

The mechanism by which *P*. *ovale* infections lead to death is still unknown, but acute renal failure and acute respiratory distress syndrome might act as secondary contributing factors to death \[[@pone.0235014.ref051]\]. People who previously acquired *P*. *falciparum* malaria and those staying in malaria-endemic regions are known to show less severe symptoms during subsequent malaria infections than are people who are from non-malaria endemic regions. A previous study investigated two cases of *P*. *ovale* in patients, and it was suggested that one patient with a history of malaria was protected against developing severe complications, while the other patient, who was experiencing malaria infection for the first time, suffered severe complications \[[@pone.0235014.ref051]\]. Therefore, severe *P*. *ovale* infections can occur in nonimmune individuals in particular.

This systematic review indicated that jaundice, severe anemia, and pulmonary impairment are the severe complications most commonly found in patients infected with *P*. *ovale*. For jaundice, a previous study indicated that mild hyperbilirubinemia can be found in approximately 50% of patients infected with *P*. *ovale* \[[@pone.0235014.ref052]\]. Jaundice concomitant with *P*. *ovale* infection might be due to liver dysfunction to conjugate bilirubin in cases of severe red blood cell destruction during malaria infection. Severe anemia concomitant with *P*. *ovale* infection might occur in patients with underlying diseases such as hemoglobinopathies, causing the severe destruction of abnormal red blood cells. The mechanism of pulmonary impairment in patients with *P*. *ovale* malaria is not clear. In patients with *P*. *falciparum* infection, cytoadherence, mechanical obstruction, and inflammation of the microvascular endothelium at the pulmonary vasculature due to infected red blood cells that cytoadhere to the microvascular endothelium causes the mechanical obstruction of pulmonary vasculature; thus, alveolar capillary permeability increases, and intravascular fluid is spread into the lungs, leading to pulmonary failure \[[@pone.0235014.ref053]\].

Summary of the evidence {#sec015}
-----------------------

The present systematic review and meta-analysis presented cases of severe manifestations and demonstrated the severity and mortality of severe *P*. *ovale* infection to increase the awareness of physicians regarding the prognosis of this disease. It is of the utmost importance to test individuals for malaria after they return from malaria-endemic areas, as severe *P*. *ovale* complications could occur, especially in nonimmune travelers. Last, the knowledge on appropriate management strategies and the necessary interventions concerning malaria diagnosis affects the severity of malaria manifestations and patient outcomes. Clinicians' and technicians' familiarity with the endemicity of malaria in an area or a region therefore plays an important role in the initial stages of laboratory assessments and subsequent diagnoses.

Limitations {#sec016}
-----------

A limitation of this systematic review and meta-analysis was that there were a limited number of available publications on severe complications and death related to *P*. *ovale* infection. Another limitation was that results from case series and case-control studies were used for prevalence estimations. However, previous studies XXX have suggested and used case reports/series in meta-analyses to facilitate the decision making process when the evidence was limited or a relatively rare or neglected disease was assessed \[[@pone.0235014.ref054]--[@pone.0235014.ref059]\]. In addition, the most recently published meta-analysis of 44 case series reported the 25-year pooled survival of hip replacements \[[@pone.0235014.ref060]\]. Considering these limitations, the meta-analysis results and conclusions on the prevalence of severity and mortality associated with *P*. *ovale* infection should be considered with caution in combination with the results of newly published reports.

Conclusion {#sec017}
==========

This systematic review demonstrated that although *P*. *ovale* infections have long been considered cases of benign malaria, severe complications in patients have been reported on rare occasions. The possible reasons for the small number of reports on the severity of the malaria infections linked or caused directly by *P*. *ovale* should be studied further by the scientific community. Clinicians and technicians need to recognize that patients who return from malaria-endemic areas may develop severe *P*. *ovale* infections. Additional studies need to consider the potential underreported presence of *P*. *ovale* malaria infections in the clinical setting so that appropriate management strategies and interventions can be administered to infected individuals and the knowledge on malaria epidemiology can be expanded further.
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